Syntetisk biologi: er ArcticZymes den nye ESG yndlingen?




Jeg har lusket litt rundt på internettet igjen og kom over dette. Helt nytt for meg og enda et ben å stå på når aksjen plutselig må regnes inn i ESG sektoren og det grønne skiftet:

« Redox enzymes require co-factors and redox partners, and there is a considerable degree of cooperativity between different enzyme classes.[1] Understanding and eventually engineering the efficient degradation of lignocellulose by these enzyme systems, a key ability in a future circular bioeconomy, requires a transdisciplinary approach far beyond “simple” enzyme discovery.
OXYMOD combines life sciences (enzyme biochemistry, enzyme production techno- logy, microbial biotechnology, high through- put screening, advanced analytics), ICT (bioinformatics, big data handling), mathe- matical sciences (enzyme systems modelling, process modelling) and engineer- ing (enzyme evolution, synthetic biology) for developing new and optimized biocatalytic systems for industrial application, primarily within the agricultural and forest sectors. It is therefore highly relevant as a project in the Norwegian Centre for Digital Life (DLN). Besides the enzymes and enzyme systems themselves, additional innovations from OXYMOD concern the generation of well- defined products streams, primarily sugars from (hemi-)cellulose and aromatic building
blocks from lignin for a variety of downstream applications (e.g. biofuels & bioplastics).»

Partnere: Borregaard og Norske Skog (!) i regi av NTNU.

Man kan lese mer her: https://www.ntnu.no/blogger/reset/wp-content/uploads/sites/32/2017/10/DLN-OXYMOD.pdf

Dokumentet er noen år gammelt og jeg lurer fælt på hvordan dette går. OXYMOD har publisert en rekke artikler i 2020 uten at jeg ble klokere av å lese dem.

Jethro har flere ganger referert til at de jobber med «noe» innen syntetisk biologi. Dette er det mest konkrete jeg har greid å finne. Antakelig enda på forsøksstadiet, så litt tålamod må man vel smøre seg med. Men jeg syntes dette var så interessant at jeg dumper det her.

Redigert 20.01.2021 kl 02:18 Du må logge inn for å svare
Midd30
01.01.2021 kl 17:14 658

Ser Vectron Biosolutions er nevnt i dokumentet til NTNU ovenfor.
Ref melding fra des 2018. Interessant!
ArcticZymes and Vectron Biosolutions sign license agreement on recombinant enzyme expression technology

(Tromsø 20. December 2018) Biotec Pharmacon’s (OSE: Biotec) subsidiary ArcticZymes and Vectron Biosolutions AS (Vectron) have signed a non-exclusive license agreement for recombinant manufacturing of enzymes.